Drugs / RhuDex®
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01500122 | Dec 2011 → Mar 2012 | — | MediGene | Completed | No outcome recorded |
| Phase 1 | NCT00704119 | May → Jul 2008 | — | MediGene | Terminated | No outcome recorded |
| Phase 1 | NCT00532012 | Sep → Oct 2007 | — | MediGene | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rhudex | “Regimen A: Rhudex Formulation in Labrafac/ Gelucire Regimen B: Rhudex Formulation in Labrafac/ Aerosil single dose” NCT01500122 ↗ |
| Known as | AV1142742 | “RhuDex® (code number AV1142742) is a novel, orally bioavailable, low molecular weight modulator of co-stimulation of T lymphocytes.” NCT00704119 ↗ |
| Action | Inhibit | “RhuDex® binds to the protein CD80 on the surface of antigen-presenting cells and inhibits its interaction with CD28” NCT00532012 ↗ |
| Modality | Small molecule | “low molecular weight modulator” NCT00532012 ↗ |
| Route | Oral | “orally bioavailable” NCT00532012 ↗ |